Reports
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
|
Tiotropium and Olodaterol (Spiolto® Respimat®) |
For COPD |
|
|
|
Tirbanibulin (Klisyri®) |
To be used where the following topical therapies are unavailable or ineffective; Diclofenac sodium 3%, Fluorouracil 5%, and Fluorouracil 0.5% and salicyclic acid 10%. |
|
|
Tirzepatide (Mounjaro®) |
Tirzepatide should not be prescribed in overweight and obesity prior to NHS England publishing their commissioning guidelines |
|
|
Tisseel |
Hospital use only |
|
|
Tobramycin nebulised |
NHS England Commissioned for Cystic Fibrosis only. Existing patients - initiated prior to April 2013 |
|
|
|
Tobramycin nebulised#3.7 |
NHS England Commissioned for Cystic Fibrosis only, new patients |
|
|
|
Tocilizumab (Tyenne® Roactemra®) |
|
Hospital use only |
|
|
Tolterodine M/R capsules |
High relative cost. Second line. |
|
|
|
Tolvaptan (Jinarc®) |
Tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease |
|
|
|
Tolvaptan (Samsca®) |
Consultant advice only. Tolvaptan (Samsca) for the treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH). |
- First page
- Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- Next page
- Last page
